This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pharma Clinical Trial Services: World Market 2013-2023

5.1.1 Benefits of Conducting Clinical Trials in Emerging National Markets

5.1.2 Challenges of Conducting Clinical Trials in Emerging Markets

5.2 Strong Growth Forecast for Emerging Clinical Trial Service Markets 2013-2023

5.3 Clinical Trials in Asia Pacific: An Emerging Market Perspective

5.3.1 India as a Hub for Clinical Trials

5.3.1.1 Increasingly Strict Regulatory Procedures in India

5.3.1.2 Indian Clinical Trial Services Market Forecast 2013-2023

5.3.2 China Will be the Largest Emerging Market for Clinical Trials Services in 2023

5.3.2.1 China Offers Many Advantages in Clinical Trials

5.3.2.2 New Guidelines for Phase I Trials

5.3.3 South Korea

5.3.3.1 Improving the Appeal of South Korea

5.3.3.2 Promoting Local Drug Development in South Korea

5.3.3.3 Growth in the South Korean Clinical Trials Services Market 2013-2023

5.4 Clinical Trial Outsourcing in Central and Eastern Europe (CEE)

5.4.1 Russia

5.4.1.1 Changing Clinical Trial Demands 2010-2012

5.4.1.2 Russian Clinical Trial Services Market Forecast 2013-2023

5.4.2 CEE: Clinical Trial Services Market Forecast 2013-2023

5.5 Latin America: Proximity to the US as a Growth Driver

5.5.1 Brazil: The Largest Market for Clinical Trials in Latin America 2013-2023

5.5.1.1 Brazilian Clinical Trial Services Market Forecast 2013-2023

6. Leading Disease Market Sectors for Clinical Trial Services 2013-2023

6.1 The Pharma Clinical Trial Services Market by Therapeutic Area 2011-20126.2 The Pharma Clinical Trial Services Market: Revenue Forecast by Therapeutic Area 2013-20236.3 Imaging for CNS and Cardiovascular Clinical Trials6.4 Cancer Clinical Trials: Key Trends and Submarket Forecast 2013-20236.4.1 Biomarkers and Companion Diagnostic Development6.4.2 Optimising Patient Recruitment and Retention6.4.3 Many Factors Complicate Cancer Clinical Trials6.4.4 The Largest Submarket for Clinical Trial Services 2013-2023?6.5 CNS Clinical Trials: Key Trends and Submarket Forecast 2013-20236.5.1 Concerns with Placebo Response Rates in CNS Clinical Trials6.5.1.1 Cogtest: Data Capture and Cognitive Assessment6.5.2 Effective Use of Adaptive Trial Designs6.5.3 CNS Clinical Trials: Submarket Forecast 2013-20236.6 Cardiovascular Disease Clinical Trials: Key Trends and Submarket Forecast 2013-20236.6.1 Strong Growth in the Cardiovascular Disease Clinical Trial Services Submarket 2013-20236.7 Infectious Disease Clinical Trials: Key Trends and Submarket Forecast 2013-20236.7.1 Challenges in the Use of Non-Inferiority Trials6.7.2 Considerations for Antibacterial Drug Clinical Trials6.7.3 Vaccine Clinical Trials and Emerging Markets6.7.4 Infectious Disease Clinical Trial Services Submarket Forecast 2013-20236.8 Metabolic Disease Clinical Trials: Key Trends and Submarket Forecast 2013-20236.8.1 Assessing Cardiovascular Risks in Diabetes6.8.2 Metabolic Disease Clinical Trial Services Submarket Forecast 2013-20236.9 Therapeutic Expertise Provides an Opportunity for Specialisation6.9.1 CROs Offering Imaging Services

5 of 13

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,059.82 +80.69 0.48%
S&P 500 1,992.60 +6.09 0.31%
NASDAQ 4,529.1950 +2.7130 0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs